

ad
3. (Amended) A polypeptide according to claim 1 or claim 47, wherein the immunogenic portion binds to an MHC class II molecule.

A2
6. (Amended) A polypeptide according to claim 1 or claim 47, wherein the polypeptide comprises 4-16 consecutive amino acids of a native WT1 polypeptide.

7. (Amended) A polypeptide according to claim 1 or claim 47, wherein the polypeptide comprises 8-10 consecutive amino acids of a native WT1 polypeptide.

Please add new claims 47-55 to read as follows:

47. (New) A polypeptide comprising at least an immunogenic portion of an amino acid sequence of SEQ ID NO:335, or a variant thereof that differs in substitutions at between 1 and 3 amino acid positions, such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.

48. (New) The polypeptide of claim 1 or claim 47 wherein said immunogenic portion comprises amino acid residues 117-139 of WT1.

A3
49. (New) The polypeptide of claim 1 or claim 47 wherein said immunogenic portion comprises amino acid residues 130-138 of WT1.

50. (New) The polypeptide of claim 1 or claim 47 wherein said polypeptide does not include the His tag of SEQ ID NO:335.

51. (New) A composition comprising any one of the polypeptides of claim 1 or claim 47 in combination with a pharmaceutically acceptable carrier or excipient.

52. (New) An immunogenic composition comprising any one of the polypeptides of claim 1 or claim 47 in combination with a non-specific immune response enhancer.

53. (New) The immunogenic composition according to claim 52 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.